For UK healthcare professionals only

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

This webinar is broadcast in association with the British Journal of Cardiology; our media partner is GPnotebook, who have had no input into the content of the activity.

ESC Congress 2024 highlights

A UK perspective

Simplifying the management of heart failure across the
ejection fraction

This is a promotional symposium sponsored and organised by AstraZeneca and is intended for GB HCPs only.

CPD accreditation has been sought for this webinar (1.0 point)

To ask a question, please enter the name you registered with. All questions will be posted anonymously.

If you’re experiencing any technical issues, please email bookings@omniamed.com

Prescribing information for Forxiga (dapagliflozin) in Great Britain is available here.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com or by calling 0800 783 0033
If you have any questions, comments or queries or would like to request an appointment with an AstraZeneca representative, you can do so here.

This site is intended for UK healthcare professionals only

To continue, please confirm that you are a UK healthcare professional.